Sanofi’s clinical trial of hemophilia A therapy in children meets endpoint

Sanofi has announced that the XTEND-Kids Phase III clinical trial of ALTUVIIIO in previously treated patients younger than 12 years of age with severe hemophilia A met its primary safety endpoint.